Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Cefixime vs IV Beta-Lactams for Liver Abscess
NCT06847126Phase 3Recruiting
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Feb 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cefixime in liver abscess (2 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoints: Clinical cure at 8 weeks and Treatment failure at 8 weeks. Started Feb 2025; status: recruiting.
02
Drugs
cefixime
03
Conditions
liver abscess
Beyond the preview
Go deeper on NCT06847126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06847126.